Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$44.45 USD
+1.81 (4.25%)
Updated Sep 19, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Income Statements
Fiscal Year end for Tandem Diabetes Care, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 748 | 801 | 703 | 499 | 362 |
Cost Of Goods | 380 | 388 | 327 | 238 | 168 |
Gross Profit | 368 | 413 | 376 | 261 | 194 |
Selling & Adminstrative & Depr. & Amort Expenses | 601 | 506 | 354 | 268 | 211 |
Income After Depreciation & Amortization | -233 | -93 | 23 | -8 | -17 |
Non-Operating Income | 23 | 6 | -1 | -16 | -8 |
Interest Expense | 10 | 6 | 6 | 13 | 0 |
Pretax Income | -220 | -93 | 16 | -36 | -25 |
Income Taxes | 2 | 2 | 0 | -2 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -223 | -95 | 16 | -34 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -223 | -95 | 16 | -34 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -212 | -72 | 39 | 11 | -11 |
Depreciation & Amortization (Cash Flow) | 22 | 20 | 16 | 19 | 6 |
Income After Depreciation & Amortization | -233 | -93 | 23 | -8 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 64.97 | 64.15 | 64.35 | 60.99 | 58.51 |
Diluted EPS Before Non-Recurring Items | -1.57 | -0.74 | 0.26 | -0.39 | -0.22 |
Diluted Net EPS (GAAP) | -3.43 | -1.47 | 0.24 | -0.56 | -0.42 |
Fiscal Year end for Tandem Diabetes Care, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 221.91 | 191.67 | 196.80 | 185.62 | 195.92 |
Cost Of Goods | 109.12 | 97.00 | 103.50 | 95.87 | 94.18 |
Gross Profit | 112.79 | 94.67 | 93.30 | 89.75 | 101.74 |
SG&A, R&D, and Dept/Amort Expenses | 143.57 | 136.35 | 128.35 | 121.30 | 140.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | -30.78 | -41.68 | -35.05 | -31.55 | -38.80 |
Non-Operating Income | 2.82 | 4.05 | 5.55 | 5.66 | 5.78 |
Interest Expense | 1.79 | 1.90 | 1.80 | 4.84 | 1.61 |
Pretax Income | -29.74 | -39.53 | -31.31 | -30.73 | -34.63 |
Income Taxes | 1.07 | 3.19 | -1.31 | 2.23 | 1.15 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -30.81 | -42.72 | -30.00 | -32.96 | -35.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -30.81 | -42.72 | -30.00 | -32.96 | -35.78 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 64.99 | 65.33 | 65.37 | 65.12 | 64.83 |
Diluted EPS Before Non-Recurring Items | -0.47 | -0.63 | -0.27 | -0.38 | -0.30 |
Diluted Net EPS (GAAP) | -0.47 | -0.65 | -0.45 | -0.51 | -0.55 |